Page 2 - Agvhd News Today

This article will appear in the January 2024 issue of Evidence-Based Oncology.™ Each year, our January issue features a recap of proceedings from the American Society of Hematology Meeting and Exposition.

"The findings suggest that early detection and management of vitiligo lesions can be improved by estimating the likelihood of its development in transplant recipients..."

The three-year final analysis of efficacy and safety of the REACH3 trial showed that patients with steroid-refractory or dependent chronic graft-versus-host disease benefited more with Jakafi compared with the best available treatment.

The panel closes by reviewing the patient case once more and shares clinical pearls on the treatment of patients with GVHD.

GVHD experts outline the treatment options for patients with steroid-refractory chronic GVHD.

Dr Gooptu highlights how she selects therapy for a patient who is refractory to steroids for chronic GVHD and Dr Inyang notes the adverse events seen with these therapies.

The panel provides an overview of the frontline treatments available for chronic GVHD.

Dr Gooptu discusses the incidence of chronic GVHD and ruminates on how a patient’s medical history may impact their chronic GVHD risk.

Mahasweta Gooptu, MD shares insights on the early identification and diagnosis of chronic GVHD.

Researchers have found a new risk biomarker that can detect the early beginnings of graft-versus-host disease in new study.